Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Observational Study on Skeletal Ewing's Sarcoma

NCT04845893 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2021-06-01
Last updated
2026-01-02

Condition(s) studied

Ewing Sarcoma of Bone

Investigational drug(s) / intervention(s)

Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)

Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments): This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments

Study summary

Observational prospective trial aimed to collect the collect demographic, clinical, surgical, pathological and molecular characteristics and treatment from patients affected by skeletal Ewing Sarcoma

Eligibility

Sex
ALL
Min age
0 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Diagnosis of Ewing's sarcoma of the bone 2. Diagnosis of Ewing-like sarcoma (round cell sarcoma with fusion of the EWSR1 gene with others not of the ETS family, sarcoma with CIC rearrangement or sarcoma with BCOR rearrangement) 3. Diagnosis of extraosseous Ewing's sarcoma for patients 4. Age at diagnosis \<50 years 5. Assessment of the extent of the disease at onset in accordance with the European Society of Medical Oncology guidelines 6. Patients or parents oe guardians of minors who have given their written informed consent to participate in the study Exclusion Criteria: 1\. Presence of comorbid factors who can compromise the compliance of the treatment plan or the evaluation of the outcomes, including but not limited to organ pathologies that contraindicate the use of chemotherapy and psychological or social conditions that do not allow for adequate compliance treatment or adequate follow-up

Primary outcome measure(s)

  • 5 years Event Free Survival (EFS) — 5 years
    Onset of any event (an event is the defined as disease recurrence, death for disease or any other cause)

Trial sites (19)

FacilityCityRegionStatus
Istituto Clinico Humanitas Rozzano MI Recruiting
Centro di Riferimento Oncologico - Unit of Medical Oncology Aviano Pordenone Recruiting
I.R.C.C. - Unit of Medical Oncology Candiolo Torino Recruiting
Azienda ospedaliero universitaria consorziale policlinico - bari Bari Italy Recruiting
A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna Bologna Italy Recruiting
Istituto ortopedico Rizzoli Bologna Italy Recruiting
A.O. Universitaria Meyer Florence Italy Recruiting
Istituto Giannina Gaslini Genova Italy Recruiting
FONDAZIONE IRCCS Istituto Nazionale dei Tumori Milan Italy Recruiting
FONDAZIONE IRCCS Istituto Nazionale dei Tumori Milan Italy Recruiting
Azienda Ospedaliera Santobono Pausilipon Naples Italy Not Yet Recruiting
Azienda Ospedaliera di Padova Padova Italy Recruiting
ARNAS P. O. "Civico e Benfratelli" Palermo Italy Recruiting
Azienda Ospedaliera Universitaria di Parma Parma Italy Recruiting
Azienda Ospedaliero-Universitaria Pisana Pisa Italy Recruiting
Ospedale Pediatrico Bambin Gesu' Roma Italy Not Yet Recruiting
Istituto Regina Elena - IFO Rome Italy Recruiting
Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology Torino Italy Recruiting
IRCCS materno infantile Burlo Garofolo Trieste Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04845893 on ClinicalTrials.gov ↗ ← All trials in Italy